Hepatitis C virus (Flaviviridae: Hepacivirus: Hepacivirus C): regulation of signaling reactions of innate immunity

Cover Image

Cite item

Full Text

Abstract

Studying the regulation of signaling reactions of innate immunity by the hepatitis C virus (HCV) will help to reveal the causes of the transition of the acute form of the disease to a chronic course. The molecular mechanisms of activation by HCV RNA of innate immunity receptors TLR and RLR and signal transduction processes leading to the synthesis of IFN and inflammatory cytokines are considered. The inhibitory effects of non-structural and structural HCV proteins on immune signaling reactions are analyzed in detail. The information presented is the result of an analysis of literature data published in international databases mainly over the past 5 years. In conclusion, signaling receptors are proposed as targets for the development of new antiviral drugs with immunotherapeutic activity.

About the authors

T. M. Sokolova

D.I. Ivanovsky Institute of Virology of National Research Centre for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya

Author for correspondence.
Email: tmsokolovavir@mail.ru
ORCID iD: 0000-0003-0957-4513

PhD (Biology), Leading Researcher, Laboratory of Cell Engineering, Academician of RANS

Moscow, 123098

Russian Federation

References

  1. Tsukiyama–Kohara K., Kohara M. Hepatitis C virus: viral quasispecies and genotypes. Int. J. Mol. Sci. 2017; 19(1): 23. https://doi.org/10.3390/ijms19010023
  2. Borgia S.M., Hedskog C., Parhy B., Hyland R.H., Stamm L.M., Brainard D.M., et al. Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C Virus into 8 genotypes. J. Infect. Dis. 2018; 218(11): 1722–9. https://doi.org/10.1093/infdis/jiy401
  3. ВОЗ. Гепатит С. Available at: https://www.who.int/ru/news-room/fact-sheets/detail/hepatitis-c
  4. Duncan J.D., Urbanowicz R.A., Tarr A.W., Ball J.K. Hepatitis C virus vaccine: challenges and prospects. Vaccines (Basel). 2020; 8(1):90. https://doi.org/10.3390/vaccines8010090
  5. Ferreira A.R., Ramos B., Nunes A., Ribeiro D. Hepatitis C virus: evading the intracellular innate immunity. J. Clin. Med. 2020; 9(3):790. https://doi.org/10.3390/jcm9030790
  6. Chigbu D.I., Loonawat R., Sehgal M., Patel D., Jain P. Hepatitis C virus infection: host-virus interaction and mechanisms of viral persistence. Cells. 2019; 8(4): 376. https://doi.org/10.3390/cells8040376
  7. Wong M.T., Chen S.S.L. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell. Mol. Immunol. 2016; 13(1): 11–35. https://doi.org/10.1038/cmi.2014.127
  8. Xu Y., Zhong J. Innate immunity against hepatitis C virus. Curr. Opin. Immunol. 2016; 42: 98–104. https://doi.org/10.1016/j.coi.2016.06.009
  9. Chen S., Wu Z., Wang M., Cheng A. Innate immune evasion mediated by flaviviridae non-structural proteins. Viruses. 2017; 9(10):291. https://doi.org/10.3390/v9100291
  10. Spengler U. Direct antiviral agents (DAAs) – А new age in the treatment of hepatitis C virus infection. Pharmacol. Ther. 2018; 183: 118–26. https://doi.org/10.1016/j.pharmthera.2017.10.009
  11. Sung P.S., Shin E.C. Interferon response in hepatitis C virus-infected hepatocytes: issues to consider in the era of direct-acting antivirals. Int. J. Mol. Sci. 2020; 21(7): 2583. https://doi.org/10.3390/ijms21072583
  12. Ning G., Li Y.T., Chen Y.M., Zhang Y., Zeng Y.F., Lin C.S. Dynamic changes of the frequency of classic and inflammatory monocytes subsets and natural killer cells in chronic hepatitis C patients treated by direct-acting antiviral agents. Can. J. Gastroenterol. Hepatol. 2017; 3612403. https://doi.org/10.1155/2017/36124030
  13. Черных Е.Р., Олейник Е.А., Леплина О.Ю., Старостина Н.М., Останин А.А. Дендритные клетки в патогенезе вирусного гепатита С. Инфекция и иммунитет. 2019; 9(2): 239–52. https://doi.org/10.15789/2220-7619-2019-2-239-252
  14. Ramirez S., Bukh J. Current status and future development of infectious cell–culture models for the major genotypes of hepatitis C virus: Essential tools in testing of antivirals and emerging vaccine strategies. Antiviral Res. 2018; 158: 264–87. https://doi.org/10.1016/j.antiviral.2018.07.014
  15. Masalova О.V., Lesnova E.I., Solyev P.N., Zakirova N.F., Prassolov V.S., Kochetkov S.N., et al. Modulation of cell death pathways by hepatitis C virus proteins in Huh7.5 hepatoma cells. Int. J. Mol. Sci. 2017; 18: 2346. https://doi.org/10.3390/ijms18112346
  16. Brubaker S.W., Bonham K.S., Zanoni I., Kagan J.C. Innate immune pattern recognition: a cell biological perspective. Annu. Rev. Immunol. 2015; 33: 257–90. https://doi.org/10.1146/annurevimmunol-032414-112240
  17. Соколова Т.М. Иммунное узнавание вирусных нуклеиновых кислот приводит к индукции интерферонов (ИФН) и воспалительных цитокинов. В кн.: Ершов Ф.И., Наровлянский А.Н., ред. Сборник научных трудов «Интерферон–2011». М.; 2012: 52–62.
  18. Yang D.R., Zhu H.Z. Hepatitis C Virus and antiviral innate immunity: who wins at tug-of-war? World. J. Gastroenterol. 2015; 21(13):3786–800. https://doi.org/10.3748/wjg.v21.i13.3786
  19. Arnaud N., Dabo S., Maillard P., Budkowska A., Kalliampakou K.I., Mavromara P., et al. Hepatitis C virus controls interferon production through PKR activation. PLoS One. 2010; 5(5): e10575. https://doi.org/10.1371/journal.pone.0010575
  20. Brisse M., Ly H. Comparative structure and function analysis of the RIG-I-like receptors: RIG-I and MDA5. Front. Immunol. 2019; 10:1586. https://doi.org/10.3389/fimmu.2019.01586
  21. Hei L., Zhong J. Laboratory of Genetics and Physiology 2 (LGP2) plays an essential role in hepatitis C virus infection-induced interferon responses. Hepatology. 2017; 65(5): 1478–91. https://doi.org/10.1002/hep.29050
  22. Bender S., Reuter A., Eberle F., Einhorn E., Binder M., Bartenschlager R. Activation of type I and III interferon response by mitochondrial and peroxisomal MAVS and inhibition by hepatitis C virus. PLoS. Pathog. 2015; 11(11): e1005264. https://doi.org/10.1371/journal.ppat.1005264
  23. Ran Y., Shu H.B., Wang Y.Y. MITA/STING: a central and multifaceted mediator in innate immune response. Cytokine Growth Factor Rev. 2014; 25(6): 631–9. https://doi.org/10.1016/j.cytogfr.2014.05.003
  24. Ding Q., Cao X., Lu J., Huang B., Liu Y.J., Kato N., et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatol. 2013; 59(1): 52–8. https://doi.org/10.1016/j.jhep.2013.03.019
  25. Ashfaq U.A., Iqbal M.S., Khaliq S. Role of toll-like receptors in hepatitis C virus pathogenesis and treatment. Crit. Rev. Eukaryot. Gene Expr. 2016; 26(4): 353–62. https://doi.org/10.1615/CritRevEukaryotGeneExpr.2016017455
  26. Zhang Z., Ohto U., Shimizu T. Toward a structural understanding of nucleic acid-sensing Toll-like receptors in the innate immune system. FEBS Letters. 2017; 591: 3167–81. https://doi.org/10.1002/1873-3468.12749
  27. Grünvogel O., Colasanti O., Lee J.Y., Klöss V., Belouzard S., Reustle A., et al. Secretion of hepatitis C virus replication intermediates reduces activation of toll-like receptor 3 in hepatocytes. Gastroenterology. 2018; 154 (8): 2237–51.е16. https://doi.org/10.1053/j.gastro.2018.03.020
  28. Dreux M., Garaigorta U., Boyd B., Decembre E., Chung J., Whitten- Bauer C., et al. Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. Cell. Host Microbe. 2012; 12(4): 558–70. https://doi.org/10.1016/j.chom.2012.08.010
  29. Szabo A., Rajnavolgyi E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses. Am. J. Clin. Exp. Immunol. 2013; 2(3): 195–207.
  30. Bruening J., Weigel B., Gerold G.J. The role of type iii interferons in hepatitis C virus infection and therapy. Immunol. Res. 2017; 7232361. https://doi.org/10.1155/2017/7232361
  31. Wang W., Xu L., Su J., Peppelenbosch M.P., Pan Q. Transcriptional regulation of antiviral interferon-stimulated genes. Trends Microbiol. 2017; 25(7): 573–84. https://doi.org/ 10.1016/j.tim.2017.01.001
  32. Li Y., Yamane D., Masaki T., Lemon S.M. The yin and yang of hepatitis C: synthesis and decay of HCV RNA. Nat. Rev. Microbiol. 2015; 13(9): 544–58. https://doi.org/10.1038/nrmicro3506
  33. Amador-Cañizares Y., Bernier A., Wilson J.A., Sagan S.M. МiR- 122 does not impact recognition of the HCV genome by innate sensors of RNA but rather protects the 5’ end from the cellular pyrophosphatases, DOM3Z and DUSP11. Nucleic Acids Res. 2018; 46(10): 5139–58. https://doi.org/10.1093/nar/gky273
  34. Schnell G., Loo Y.M., Marcotrigiano J., Gale M. Uridine composition of the poly-U/UC tract of HCV RNA defines non-self recognition by RIGI. PLoS Pathog. 2012; 8(8): e1002839. https://doi.org/10.1371/journal.ppat.1002839
  35. Dabo S., Meurs E.F. dsRNA-dependent protein kinase PKR and its role in stress, signaling and HCV infection. Viruses. 2012; 4(11):2598–635. https://doi.org/10.3390/v4112598
  36. Toroney R., Nallagatla S.R., Boyer J.A., Cameron C.E., Bevilacqua P.C. Regulation of PKR by HCV IRES RNA: Importance of domain II and NS5A. J. Mol. Biol. 2010; 400(3): 393–412. https://doi.org/10.1016/j.jmb.2010.04.059
  37. Imran M., Waheed Y., Manzoor S., Bilal M., Ashraf W., Ali M., et al. Interaction of hepatitis C virus proteins with pattern recognition receptors. Virol. J. 2012; 9: 126. https://doi.org/10.1186/1743-422x-9-126
  38. Chung H., Watanabe T., Kudo M., Chiba T. Hepatitis C virus core protein induces homotolerance and cross-tolerance to toll-like receptor ligands by activation of toll-like receptor 2. J. Infect. Dis. 2010; 202(6): 853–61. https://doi.org/10.1086/655812
  39. Kaukinen P., Sillanpaa M., Nousiainen L., Melen K., Julkunen I. Hepatitis C virus NS2 protease inhibits host cell antiviral response by inhibiting IKKepsilon and TBK1 functions. J. Med. Virol. 2013; 85(1): 71–82. https://doi.org/10.1002/jmv.23442
  40. Zhou H., Qian Qi., Shu T., Xu J., Kong J., Mu J., et al. Hepatitis C virus NS2 protein suppresses RNA interference in cells. Virol. Sin. 2019; 35(4): 1–9. https://doi.org/10.1007/s12250-019-00182-5
  41. Yan Y., He Y., Boson B., Wang X., Cosset F. L., Zhong J.A. Point mutation in the N-terminal amphipathic helix α(0) in NS3 promotes hepatitis virus assembly by altering core localization to the endoplasmic reticulum and facilitating virus budding. J. Virol. 2017; 91(6): e02399–16. https://doi.org/10.1128/JVI.02399-16
  42. Ferreon J.C., Ferreon C.M., Li K., Lemon S.M. Molecular determinants of TRIF proteolysis mediated by the hepatitis C virus NS3/4A protease. J. Biol. Chem. 2005; 280(21): 20483–92. https://doi.org/10.1074/jbc.M500422200
  43. Ferreira A.R., Magalhães A.C., Camões F., Gouveia A., Vieira M., Kagan J.C., et al. Hepatitis C virus NS3–4A inhibits the peroxisomal MAVS-dependent antiviral signaling response. J. Cell Mol. Med. 2016; 20(4): 750–7. https://doi.org/10.1111/jcmm.12801
  44. Vazquez C., Tan C.Y., Horner S.M. Hepatitis C virus infection is inhibited by a non-canonical antiviral signaling pathway targeted by NS3-NS4A. J. Virol. 2019; 93(23) e00725-19. https://doi.org/10.1128/JVI.00725-19
  45. Chen Y., He L., Peng Y., Shi X., Chen J., Zhong J., et al. The hepatitis C virus protein NS3 suppresses TNF-stimulated activation of NF-kB by targeting LUBAC. Sci. Signal. 2015; 8(403): ra118. DOI: https://doi.org/10.1126/scisignal.aab2159
  46. Nitta S., Sakamoto N., Nakagawa M., Kakinuma S., Mishima K., Kusano-Kitazume A., et al. Hepatitis C virus NS4B protein targets STING and abrogates RIG-I-mediated type I interferon-dependent innate immunity. Hepatology. 2013; 57(1): 46–58. https://doi.org/10.1002/hep.26017
  47. Ding Q., Cao X., Lu J., Huang B., Liu Y.J., Kato N., et al. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatol. 2013; 59(1): 52–8. https://doi.org/10.1016/j.jhep.2013.03.019
  48. Yi G., Wen Y., Shu C., Han Q., Konan K.V., Li P., et al. The hepatitis C virus NS4B Can suppress STING accumulation to evade innate immune responses. J. Virol. 2015; 90(1): 254–65. DOI: https://doi.org/10.1128/JVI.01720–15
  49. Horner S.M., Liu H.M., Park H.S., Briley J., Gale M. Mitochondrial- associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. Proc. Nat. Acad. Sci. USA. 2011; 108(35): 14590–5. https://doi.org/10.1073/pnas.1110133108
  50. Liang Y., Cao X., Ding Q., Zhao Y., He Z., Zhong J. Hepatitis C virus NS4B induces the degradation of TRIF to inhibit TLR3-mediated interferon signaling pathway. PLoS Pathog. 2018; 14(5):e1007075. https://doi.org/10.1371/journal.ppat.1007075
  51. Kong L., Li S., Huang M., Xiong Y., Zhang Q., Ye L., et al. The roles of endoplasmic reticulum overload response induced by HCV and NS4B protein in human hepatocyte viability and virus replication. PLoS One. 2015; 10(4): e0123190. https://doi.org/10.1371/journal.pone.0123190
  52. Hiet M.S., Bauhofer O., Zayas M., Roth H., Tanaka Y., Schirmacher P., et al. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J. Hepatol. 2015; 63(4): 829–37. https://doi.org/10.1016/j.jhep.2015.04.015
  53. Sugiyama R., Murayama A., Nitta S., Yamada N., Tasaka-Fujita M., Masaki T., et al. Interferon sensitivity–determining region of hepatitis C virus influences virus production and interferon signaling. Oncotarget. 2018; 9(5): 5627-40. https://doi.org/10.18632/oncotarget.23562
  54. Abe T., Kaname Y., Hamamoto I., Tsuda Y., Wen X., Taguwa S., et al. Hepatitis C virus nonstructural protein 5A modulates the Toll-like receptor- MyD88-dependent signaling pathway in macrophage cell lines. J. Virol. 2007; 81(17): 8953–66. https://doi.org/10.1128/JVI.00649-07
  55. Chowdhury J.B., Kim H., Ray R., Ray R.B. Hepatitis C virus NS5A protein modulates IRF-7-mediated interferon-β signaling. J. Interferon Cytokine Res. 2014; 34(1): 16–21. https://doi.org/10.1089/jir.2013.0038
  56. Kumthip K., Chusri P., Jilg N., Zhao L., Fusco D.N., Zhao H., et al. Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling. J. Virol. 2012; 86(16): 8581–91. https://doi.org/10.1128/JVI.00533-12
  57. Çevik R.E., Cesarec M., Da A., Filipe S., Licastro D., Mclauchlan J., et al. Hepatitis C virus NS5A targets nucleosome assembly protein NAP1L1 to control the innate cellular response. J. Virol. 2017; 91(18): e00880–17. https://doi.org/10.1128/JVI.00880-17
  58. Nitta S., Asahina Y., Matsuda M., Yamada N., Sugiyama R., Masaki T., et al. Effects of resistance–associated NS5A mutations in hepatitis C virus on viral production and susceptibility to antiviral reagents. Sci. Rep. 2016; 6: 34652. https://doi.org/10.1038/srep34652
  59. Polyak S.J., Khabar K.S., Rezeiq M., Gretch D.R. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 2001; 75(13): 6209–11. https://doi.org/10.1128/JVI.75.13.6209-6211.2001
  60. Miyasaka Y., Enomoto N., Kurosaki M., Sakamoto N., Kanazawa N., Kohashi T., et al. Hepatitis C virus nonstructural protein 5A inhibits tumor necrosis factor-a-mediated apoptosis in Huh7 cells. J. Infect. Dis. 2003; 188(10): 1537–44. https://doi.org/10.1086/379253
  61. Zhang Q., Wang Y., Zhai N., Song H., Li H., Yang Y., et al. HCV core protein inhibits polarization and activity of both M1 and M2 macrophages through the TLR2 signaling pathway. Sci. Rep. 2016; 6: 36160. https://10.1038/srep36160
  62. Dolganiuc A., Chang S., Kodys K., Mandrekar P., Bakis G., Cormier M., et al. Hepatitis C virus (HCV) core protein-induced, monocyte- mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J. Immunol. 2006; 177(10): 6758–68. https://doi.org/10.4049/jimmunol.177.10.6758
  63. Luquin E., Larrea E., Civeira M.P., Prieto J., Aldabe R. HCV structural proteins interfere with interferon-alpha Jak/STAT signalling pathway. Antiviral Res. 2007; 76(2): 194–7. https://doi.org/10.1016/j.antiviral.2007.06.004
  64. Stone A.E.L., Mitchell A., Brownell J., Miklin D.J., Golden-Mason L., Polyak S.J., et al. Hepatitis C virus core protein inhibits interferon production by a human plasmacytoid dendritic cell line and dysregulates interferon regulatory factor-7 and Signal Transducer and Activator of Transcription (STAT) 1 protein expression. PLoS One. 2014; 9(5): e95627. https://doi.org/10.1371/journal.pone.0095627
  65. Bode J.G., Ludwig S., Ehrhardt C., Albrecht U., Erhardt A., Schaper F., et al. IFN-alpha antagonistic activity of HCV core protein involves induction of suppressor of cytokine signaling-3. FASEB J. 2003; 17(3): 488–90. https://doi.org/10.1096/fj.02–0664fje
  66. Negash A.A., Olson R.M., Griffin S., Gale M. Modulation of calcium signaling pathway by hepatitis C virus core protein stimulates NLRP3 inflammasome activation. PLoS Pathog. 2019; 15(2):e1007593. https://doi.org/10.1371/journal.ppat.1007593
  67. Ivanov A.V., Smirnova O.A., Petrushanko I.Yu., Ivanova O.N., Karpenko I.L., Alekseeva E., et al. HCV core protein uses multiple mechanisms to induce oxidative stress in human hepatoma Huh7 cells. Viruses. 2015; 7(6): 2745–70. https://doi.org/10.1371/journal.ppat.1007593
  68. Parvaiz F., Manzoor S., Tariq H., Javed F., Fatima K., Qadri I. Hepatitis C virus infection: molecular pathways to insulin resistance. Virol. J. 2011; 8: 474. https://doi.org/10.1186/1743-422X-8-474
  69. Cao L., Yu B., Kong D., Cong Q., Yu T., Chen Z., et al. Functional expression and characterization of the envelope glycoprotein E1E2 heterodimer of hepatitis C virus. PLoS Pathog. 2019; 15(5):e1007759. https://doi.org/10.1371/journalppat.1007759
  70. Bolcic F., Sede M., Moretti F., Westergaard G., Vazquez M., Laufer N., et al. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment. Arch. Virol.2012; 157(4):703–11. https://doi.org/10.1007/s00705-012-1230-1
  71. Qi H., Chu V., Wu N.C., Chen Z., Truong S., Brar G., et al. Systematic identification of anti-interferon function on hepatitis C virus genome reveals p7 as an immune evasion protein. Proc. Natl. Acad. Sci. USA. 2017; 114(8): 2018–23. https://doi.org/10.1073/pnas.1614623114

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Sokolova T.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Согласие на обработку персональных данных с помощью сервиса «Яндекс.Метрика»

1. Я (далее – «Пользователь» или «Субъект персональных данных»), осуществляя использование сайта https://journals.rcsi.science/ (далее – «Сайт»), подтверждая свою полную дееспособность даю согласие на обработку персональных данных с использованием средств автоматизации Оператору - федеральному государственному бюджетному учреждению «Российский центр научной информации» (РЦНИ), далее – «Оператор», расположенному по адресу: 119991, г. Москва, Ленинский просп., д.32А, со следующими условиями.

2. Категории обрабатываемых данных: файлы «cookies» (куки-файлы). Файлы «cookie» – это небольшой текстовый файл, который веб-сервер может хранить в браузере Пользователя. Данные файлы веб-сервер загружает на устройство Пользователя при посещении им Сайта. При каждом следующем посещении Пользователем Сайта «cookie» файлы отправляются на Сайт Оператора. Данные файлы позволяют Сайту распознавать устройство Пользователя. Содержимое такого файла может как относиться, так и не относиться к персональным данным, в зависимости от того, содержит ли такой файл персональные данные или содержит обезличенные технические данные.

3. Цель обработки персональных данных: анализ пользовательской активности с помощью сервиса «Яндекс.Метрика».

4. Категории субъектов персональных данных: все Пользователи Сайта, которые дали согласие на обработку файлов «cookie».

5. Способы обработки: сбор, запись, систематизация, накопление, хранение, уточнение (обновление, изменение), извлечение, использование, передача (доступ, предоставление), блокирование, удаление, уничтожение персональных данных.

6. Срок обработки и хранения: до получения от Субъекта персональных данных требования о прекращении обработки/отзыва согласия.

7. Способ отзыва: заявление об отзыве в письменном виде путём его направления на адрес электронной почты Оператора: info@rcsi.science или путем письменного обращения по юридическому адресу: 119991, г. Москва, Ленинский просп., д.32А

8. Субъект персональных данных вправе запретить своему оборудованию прием этих данных или ограничить прием этих данных. При отказе от получения таких данных или при ограничении приема данных некоторые функции Сайта могут работать некорректно. Субъект персональных данных обязуется сам настроить свое оборудование таким способом, чтобы оно обеспечивало адекватный его желаниям режим работы и уровень защиты данных файлов «cookie», Оператор не предоставляет технологических и правовых консультаций на темы подобного характера.

9. Порядок уничтожения персональных данных при достижении цели их обработки или при наступлении иных законных оснований определяется Оператором в соответствии с законодательством Российской Федерации.

10. Я согласен/согласна квалифицировать в качестве своей простой электронной подписи под настоящим Согласием и под Политикой обработки персональных данных выполнение мною следующего действия на сайте: https://journals.rcsi.science/ нажатие мною на интерфейсе с текстом: «Сайт использует сервис «Яндекс.Метрика» (который использует файлы «cookie») на элемент с текстом «Принять и продолжить».